Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2013 | 12-2012 | 09-2012 | 06-2012 | 03-2012 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,318 | 1,222 | 1,842 | 4,072 | 4,900 |
| TOTAL | $4,459 | $1,222 | $1,858 | $4,144 | $4,954 |
| Non-Current Assets | |||||
| PPE Net | 28 | 30 | 31 | 33 | 35 |
| Intangibles | 4,758 | 4,926 | 5,094 | 5,262 | 5,429 |
| Other Non-Current Assets | 27 | 27 | 27 | 27 | 27 |
| TOTAL | $4,813 | $4,983 | $5,152 | $5,322 | $5,491 |
| Total Assets | $9,272 | $6,205 | $7,011 | $9,466 | $10,445 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 50 | 243 | 281 | 189 | 313 |
| Accrued Expenses | 141 | 61 | 1,536 | 1,428 | 541 |
| TOTAL | $295 | $511 | $1,955 | $1,723 | $927 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 3,521 | 1,300 | 1,632 | 2,879 | 3,331 |
| TOTAL | $3,521 | $1,300 | $1,632 | $2,879 | $3,331 |
| Total Liabilities | $3,816 | $1,811 | $3,587 | $4,601 | $4,257 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 126,397 | 122,058 | 113,701 | 112,925 | 112,028 |
| Common Shares | 125 | 118 | 114 | 113 | 111 |
| Retained earnings | -122,523 | -118,353 | -116,432 | -114,085 | -110,252 |
| TOTAL | $5,457 | $4,394 | $3,424 | $4,865 | $6,188 |
| Total Liabilities And Equity | $9,272 | $6,205 | $7,011 | $9,466 | $10,445 |